Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 3 2Phase 1/2 2Phase 1 2

Status

Withdrawn 3Terminated 1

Sponsor Class

OTHER 5INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 2Tumor-Agnostic 1Thoracic 1Other hematologic neoplasm 1Myeloid 1Breast 1

Conditions

Neoplasms 2Neoplasm Metastasis 2Stomach Neoplasms 1Recurrence 1Pancreatic Neoplasms 1Myelodysplastic Syndromes 1Lung Neoplasms 1Leukemia, Myeloid, Acute 1Esophageal Neoplasms 1Colonic Neoplasms 1Carcinoma, Hepatocellular 1Breast Neoplasms 1Adenocarcinoma 1

Interventions

Carboplatin 272Paclitaxel 267Gemcitabine 244Bevacizumab 225Cisplatin 216pembrolizumab 213Docetaxel 210Pemetrexed 162Capecitabine 148Fluorouracil 129Oxaliplatin 121Cyclophosphamide 121Nivolumab 112Dexamethasone 99Trastuzumab 89Leucovorin 87Cetuximab 85Rituximab 83Irinotecan 82Injections 80Erlotinib Hydrochloride 70Prednisone 68Doxorubicin 68Temozolomide 67atezolizumab 65Ipilimumab 64Bortezomib 64Fulvestrant 59Radiotherapy 54Drug Therapy 51

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × INDUSTRY × devimistat × Clear all
NCT06518538 2024-08-15

Evaluate Efficacy of Devimistat in Combination With mFFX in 2nd Line Patients With Metastatic Pancreatic Cancer

Cornerstone Pharmaceuticals

Phase 2 Withdrawn
Gastrointestinal

Pancreatic Neoplasms

NCT01520805 2016-12-29

Safety and Effectiveness Study of CPI-613 to Treat Refractory or Relapsed Leukemia and Myelodysplastic Syndrome

Cornerstone Pharmaceuticals

Phase 2 Withdrawn
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Recurrence, Leukemia, Myeloid, Acute

NCT01832857 2016-12-29

Phase 2 Safety, Tolerability and Efficacy Study of CPI-613 in Cancer Patients

Cornerstone Pharmaceuticals

Phase 2 Terminated
7 enrolled
BreastGastrointestinalThoracic

Breast Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Carcinoma, Hepatocellular, Lung Neoplasms, Neoplasm Metastasis, Neoplasms, Stomach Neoplasms

NCT01830322 2013-08-14

Safety and Effectiveness Study of CPI-613 and/or Gemcitabine to Treat Metastatic Pancreatic Cancer

Cornerstone Pharmaceuticals

Phase 2 Withdrawn
Tumor-Agnostic

Adenocarcinoma, Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡